Literature DB >> 21052756

Association of melanoma and natalizumab therapy in the Italian MS population: a second case report.

A Laroni1, M Bedognetti, A Uccelli, E Capello, G L Mancardi.   

Abstract

There is debate about a possible association between natalizumab treatment and higher risk of melanoma. Here we report a case of melanoma in a patient who developed melanoma after 77 infusions of natalizumab, without known risk factors. Pharmacovigilance programs of new drugs can help to monitor adverse events in patients at risk.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21052756     DOI： 10.1007/s10072-010-0427-x

Source DB:  PubMed          Journal:  Neurol Sci        ISSN： 1590-1874            Impact factor:   3.307


  11 in total

1.  Melanoma incidence in central Italy will go on increasing also in the near future: a registry-based, age-period-cohort analysis.

Authors:  Emanuele Crocetti; Paolo Carli; Guido Miccinesi
Journal:  Eur J Cancer Prev       Date:  2007-02       Impact factor: 2.497

2.  Melanoma complicating treatment with natalizumab for multiple sclerosis.

Authors:  John T Mullen; Timothy K Vartanian; Michael B Atkins
Journal:  N Engl J Med       Date:  2008-02-07       Impact factor: 91.245

3.  Melanoma following treatment with alemtuzumab for multiple sclerosis.

Authors:  A A Pace; J P Zajicek
Journal:  Eur J Neurol       Date:  2009-04       Impact factor: 6.089

4.  More on melanoma with transdifferentiation.

Authors:  Michael A Panzara; Carmen Bozic; Alfred W Sandrock
Journal:  N Engl J Med       Date:  2008-07-03       Impact factor: 91.245

5.  Melanoma complicating treatment with natalizumab (tysabri) for multiple sclerosis.

Authors:  Azza Ismail; Julie Kemp; Basil Sharrack
Journal:  J Neurol       Date:  2009-07-16       Impact factor: 4.849

6.  Eruptive latent metastatic melanomas after initiation of antitumor necrosis factor therapies.

Authors:  Gregory J Fulchiero; Heather Salvaggio; Joseph J Drabick; Kevin Staveley-O'Carroll; Elizabeth M Billingsley; James G Marks; Klaus F Helm
Journal:  J Am Acad Dermatol       Date:  2007-05       Impact factor: 11.527

7.  Expression of the integrin alpha 4 beta 1 on melanoma cells can inhibit the invasive stage of metastasis formation.

Authors:  F Qian; D L Vaux; I L Weissman
Journal:  Cell       Date:  1994-05-06       Impact factor: 41.582

8.  Melanoma in multiple sclerosis treated with natalizumab: causal association or coincidence?

Authors:  Roberto Bergamaschi; Cristina Montomoli
Journal:  Mult Scler       Date:  2009-12       Impact factor: 6.312

9.  Regulation of integrin activity by MIA.

Authors:  Richard Bauer; Martin Humphries; Reinhard Fässler; Andreas Winklmeier; Sue E Craig; Anja-Katrin Bosserhoff
Journal:  J Biol Chem       Date:  2006-03-03       Impact factor: 5.157

10.  A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.

Authors:  Chris H Polman; Paul W O'Connor; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; David H Miller; J Theodore Phillips; Fred D Lublin; Gavin Giovannoni; Andrzej Wajgt; Martin Toal; Frances Lynn; Michael A Panzara; Alfred W Sandrock
Journal:  N Engl J Med       Date:  2006-03-02       Impact factor: 91.245
View more
  6 in total

Review 1.  Immunogenicity and other problems associated with the use of biopharmaceuticals.

Authors:  Michael G Tovey; Christophe Lallemand
Journal:  Ther Adv Drug Saf       Date:  2011-06

Review 2.  Neuroimaging of Natalizumab Complications in Multiple Sclerosis: PML and Other Associated Entities.

Authors:  Justin M Honce; Lidia Nagae; Eric Nyberg
Journal:  Mult Scler Int       Date:  2015-09-21

Review 3.  Melanoma complicating treatment with natalizumab for multiple sclerosis: A report from the Southern Network on Adverse Reactions (SONAR).

Authors:  Rachel A Sabol; Virginia Noxon; Oliver Sartor; Joseph R Berger; Zaina Qureshi; Dennis W Raisch; LeAnn B Norris; Paul R Yarnold; Peter Georgantopoulos; William J Hrushesky; Laura Bobolts; Paul Ray; Akida Lebby; Robert C Kane; Charles L Bennett
Journal:  Cancer Med       Date:  2017-06-20       Impact factor: 4.452

4.  Glioblastoma in natalizumab-treated multiple sclerosis patients.

Authors:  Fabian Sierra Morales; Robert B Wright; Jorge E Novo; Leonidas D Arvanitis; Dusan Stefoski; Igor J Koralnik
Journal:  Ann Clin Transl Neurol       Date:  2017-06-06       Impact factor: 4.511

Review 5.  Long-term safety and efficacy of natalizumab in relapsing-remitting multiple sclerosis: impact on quality of life.

Authors:  Raquel Planas; Roland Martin; Mireia Sospedra
Journal:  Patient Relat Outcome Meas       Date:  2014-04-04

6.  Multiple Sclerosis Treatment and Melanoma Development.

Authors:  Maria Luigia Carbone; Pedro Miguel Lacal; Serena Messinese; Laura De Giglio; Carlo Pozzilli; Severino Persechino; Cinzia Mazzanti; Cristina Maria Failla; Gianluca Pagnanelli
Journal:  Int J Mol Sci       Date:  2020-04-22       Impact factor: 5.923
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.